Nature Communications (Sep 2022)
Insight into mode-of-action and structural determinants of the compstatin family of clinical complement inhibitors
Abstract
Therapeutic modulation of the complement system has gained interest over the past two decades. Here, the authors provide molecular-level insight into the mode-of-action, target selectivity and species specificity of the compstatin family of complement inhibitors, which entered the clinic in 2021.